Compare EKSO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EKSO | LEXX |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 18.9M |
| IPO Year | N/A | N/A |
| Metric | EKSO | LEXX |
|---|---|---|
| Price | $7.12 | $0.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.50 | $1.50 |
| AVG Volume (30 Days) | ★ 5.9M | 1.4M |
| Earning Date | 03-02-2026 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,749,000.00 | $522,000.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | $54.65 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.05 |
| 52 Week Low | $2.73 | $0.46 |
| 52 Week High | $12.70 | $2.03 |
| Indicator | EKSO | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 47.30 |
| Support Level | $7.70 | $0.68 |
| Resistance Level | $9.11 | $0.81 |
| Average True Range (ATR) | 1.09 | 0.07 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 3.80 | 77.12 |
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.